- Home
- ME vs ATNM Comparison
ME vs ATNM Comparison
Compare ME & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ME
- ATNM
- Stock Information
- Founded
- ME 2006
- ATNM 2000
- Country
- ME United States
- ATNM United States
- Employees
- ME N/A
- ATNM N/A
- Industry
- ME Precision Instruments
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- ME Health Care
- ATNM Health Care
- Exchange
- ME Nasdaq
- ATNM Nasdaq
- Market Cap
- ME 40.0M
- ATNM 33.1M
- IPO Year
- ME N/A
- ATNM N/A
- Fundamental
- Price
- ME $1.82
- ATNM $1.20
- Analyst Decision
- ME Hold
- ATNM Strong Buy
- Analyst Count
- ME 1
- ATNM 4
- Target Price
- ME $9.40
- ATNM $8.75
- AVG Volume (30 Days)
- ME 466.4K
- ATNM 154.9K
- Earning Date
- ME 01-28-2025
- ATNM 04-25-2025
- Dividend Yield
- ME N/A
- ATNM N/A
- EPS Growth
- ME N/A
- ATNM N/A
- EPS
- ME N/A
- ATNM N/A
- Revenue
- ME $208,775,000.00
- ATNM $81,000.00
- Revenue This Year
- ME $22.00
- ATNM $138.42
- Revenue Next Year
- ME $17.31
- ATNM $16,957.05
- P/E Ratio
- ME N/A
- ATNM N/A
- Revenue Growth
- ME N/A
- ATNM N/A
- 52 Week Low
- ME $1.34
- ATNM $1.03
- 52 Week High
- ME $12.76
- ATNM $10.24
- Technical
- Relative Strength Index (RSI)
- ME 37.81
- ATNM 53.96
- Support Level
- ME $1.48
- ATNM $1.03
- Resistance Level
- ME $1.75
- ATNM $1.16
- Average True Range (ATR)
- ME 0.17
- ATNM 0.06
- MACD
- ME 0.02
- ATNM 0.01
- Stochastic Oscillator
- ME 40.43
- ATNM 91.94
About ME 23andMe Holding Co.
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.